secwatch.observer — SEC 8-K summary
======================================

Issuer:     Humacyte, Inc. (HUMA)
CIK:        0001818382
Form:       8-K
Filed at:   2024-03-04T23:59:59+00:00
Accession:  0001818382-24-000026
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Humacyte prices $40.2M public offering of 13.4M shares at $3.00 per share
-------------------------------------------------------------------------

- Offering of 13,400,000 shares at $3.00/share; gross proceeds $40.2M before underwriting discounts.
- Underwriters have 30-day option to buy up to 2,010,000 additional shares.
- Net proceeds ~$37.4M (or ~$43.1M if option exercised); closing expected March 5, 2024.
- Proceeds to fund BLA for HAVs in vascular trauma, pipeline advancement, and commercial infrastructure.
- TD Cowen and Cantor are joint book-running managers; BTIG is lead manager.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1818382/000181838224000026/0001818382-24-000026-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1818382/000181838224000026/huma-20240229.htm
  HTML page:      https://secwatch.observer/filing/0001818382-24-000026

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer